Bayer is growing in Basel
The German life sciences company Bayer wants to continue to grow in Basel, as company representatives announced in a press conference. Bayer settled in Basel in 2005. Since then, the number of employees has risen from 120 to 750. For the coming years, the group expects 100 additional employees per year. The workforce includes people from 60 nations.
Bayer. (Img: Bayer AG)
Of the 750 employees, 500 work in the Consumer Health sector, which includes non-prescription drugs such as aspirin, bepanthen or Alka-Seltzer. Since 2016, Basel is the global headquarter of this division. In addition, parts of Bayer’s pharmaceutical division are also operating from Basel. These include employees in the fields of oncology, ophthalmology and hematology. These departments recorded the largest increase in new employees.
According to Bayer, the company can chose from 7,000 applications per year. The Group benefits from the Basel Life Sciences Cluster as well as its proximity to pharmaceutical giants like Roche and Novartis.
As the company’s representatives stated, Basel’s location is not more expensive than others, but more attractive. And since employees in Basel could gain extensive experience within a short time, the location works like a talent hub for the entire group. In order to adjust to the growth, the company invested 20 million Swiss francs in the reconstruction of its office space in the Peter Merian building in Basel.
Bayer is also located in the Infrapark Baselland with an offshoot of its agrochemical division. Bepanthen is produced in Grenzach-Wyhlen. With more locations in Zurich and Zollikofen, Bayer employs more than 1200 people in Switzerland, 115’200 worldwide. In 2016, the company had a turnover of 46.8 Euro billion.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More
The Basel-based Botnar Research Center for Child Health is providing capital in the amount of 15 million Swiss francs to its four partner institutions. In this way, the University of Basel should be in a position to advance research into dealing with the coronavirus outbreak.Read More